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1. Introduction  
Multiple sclerosis (MS) is a chronic disabling autoimmune disorder of the central nervous 
system histopathologically characterized by inflammation, multifocal demyelination, axonal 
damage and neuronal loss. Focal intensive demyelination and white matter infiltration by 
lymphocytes and mononuclear cells are pathological hallmarks of the disease (Ferguson et 
al., 1997; Lucchinetti et al., 2000).   
Complementary to the clinical evaluation, conventional magnetic resonance imaging 
(cMRI) plays a prominent role for diagnosis and assessment of patients with multiple 
sclerosis. It provides reliable detection and quantitative estimation of focal white matter 
lesions in vivo. Modern criteria involve MRI parameters for the diagnosis of MS and for 
predicting conversion to clinically definite MS in patients who present with a first clinical 
episode (eg, unilateral optic neuritis) suggestive of disease onset. A diagnosis of multiple 
sclerosis is based on showing disease dissemination in space and time and excluding 
other neurological disorders that can clinically and radiologically mimic multiple 
sclerosis. However, neurological impairment of patients with MS is poorly associated 
with the lesion load observed on conventional MRI scans. The discrepancy between 
clinical and conventional MRI findings in MS is explained, at least partially, by the low 
sensitivity of conventional MRI in the detection of grey-matter involvement and diffuse 
damage in white matter.  
In order to overcome these limitations new uses of conventional MRI methods have 
evolved and nonconventional MRI techniques have been developed. These advances are 
expected to help in understanding the underlying disease processes and the accumulation 
of irreversible disability and therefore are promising tools in studies of disease evolution 
and clinical trials.   
Optical coherence tomography (OCT) -a new, sensitive and non-invasive transpupillary 
imaging method- is able to provide accurate and quantitative measurements of axonal loss 
in retina and therefore holds promise as a biomarker for neurodegeneration in MS. 
This chapter reviews the use of cMRI techniques to diagnosis and follow-up of patients with 
MS. It also summarizes the evolving non-conventional MRI and non-invasive optical 
techniques, which are sensitive to different aspects of MS pathology and are promising to 
further increase our understanding of disease pathophysiology and the mechanisms 
accounting for the accumulation of irreversible disability.  
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2. MRI and the diagnosis of multiple sclerosis 
Since multiple sclerosis is a histopathological diagnosis, clinical criteria have been 
developed for the diagnosis of MS during life. Initial diagnostic criteria were based on 
clinical features alone to show disease dissemination in space and in time (Schumacher et 
al., 1965). The introduction of MRI in clinical practice resulted in improved investigation of 
multiple sclerosis (Young et al., 1981). Paraclinical evidence to support clinical findings in 
cases of diagnostic uncertainty was first proposed by Poser and colleagues (Poser et al., 
1983). Given that MRI is the most sensitive paraclinical test and that comparable MRI 
abnormalities may be found in a variety of other diseases and in healthy volunteers, criteria 
have been developed by which MRIs can be classified as suggestive of multiple sclerosis or 
not (Fazekas et al., 1988; Paty et al., 1988; Barkhof et al., 1997; Tintore et al., 2000). 
With the increased availability of MRI scanners and the high sensitivity and ability of MRI 
to provide evidence for disease dissemination in both space and time, subsequent consensus 
criteria relied on MRI findings to complement clinical and other paraclinical data for the 
diagnosis of MS (McDonald et al., 2001). The 2001 McDonald diagnostic criteria for multiple 
sclerosis included MRI evidence of dissemination in space (DIS) and dissemination in time 
(DIT), which allowed a diagnosis of multiple sclerosis to be made in patients with clinically 
isolated syndrome (CIS) (McDonald et al., 2001). The DIS criteria were those developed for 
brain MRI by Barkhof and colleagues (1997) and Tintore and colleagues (2000), in addition 
to allowing one spinal-cord lesion to substitute for a brain lesion. Evidence for DIT requires 
either a gadolinium enhancing lesion after at least 3 months from CIS onset, or a new T2 
lesion developing on a scan subsequent to a reference scan obtained at least 3 months after 
CIS onset (Table 1). 
The incorporation of MRI findings to the diagnostic criteria improved the ability to diagnose 
MS and exclude alternative diagnoses. Apparently MRI started to play a prominent role in 
establishing a firm and clear diagnosis of multiple sclerosis and predicting conversion to 
clinically definite MS in patients who present with a first clinical episode (eg, unilateral optic 
neuritis) suggestive of disease onset. The necessity of early and accurate diagnosis became 
particularly important with the advent of disease modifying treatments. Subsequently, the 
McDonald criteria were revised in 2005 by Polman and colleagues, to simplify their use and 
increase their sensitivity while maintaining their specificity. These revised criteria 
strengthen the use of spinal cord lesions in MS diagnosis, allowing a spinal cord lesion to 
substitute for an infratentorial brain lesion. In 2006, new simpler imaging criteria were 
proposed with similar high specificity for clinically definite MS (CDMS) and increased 
sensitivity (Swanton et al., 2006), in which DIS requires at least one T2 lesion in at least two 
of four locations (juxtacortical, periventricular, infratentorial, and spinal-cord) and DIT 
requires a new T2 lesion on a follow-up scan. Thereafter, new data and consensus 
underlined the need to simplify the revised McDonald Criteria in order to improve their 
comprehension and utility.  Accumulating evidence resulted recently in specific 
recommendations for revisions to the McDonald Criteria. These proposals concerned the use 
and interpretation of imaging criteria for DIS and DIT and were based on the simplified 
criteria of Swanton and colleagues (Polman et al., 2011). The 2010 revisions to the McDonald 
Criteria simplify the diagnostic process with fewer required MRI examinations, allowing a 
more rapid diagnosis of MS, with preserved or improved specificity and sensitivity 
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compared with past Criteria (Table 2). However, even these latest revisions do not address 
issues of lesion morphology except to emphasize the importance of Gd enhancement and 
insufficiently deal with lesion location. Distribution and morphology provide important 
clues to the suspected nature of the detected lesions. In addition, misapplication of the 
McDonald criteria can lead to misdiagnosis in subjects without relevant clinical symptoms. 
Therefore, a diagnosis of MS based on incidental findings on MRI alone, should be avoided 
(Polman et al., 2011). 
 
Clinical Presentation Additional Data Needed 
 2 or more attacks (relapses) 
 2 or more objective clinical lesions 
None; clinical evidence will suffice  
(additional evidence desirable but must be 
consistent with MS)  
 2 or more attacks 
 1 objective clinical lesion 
Dissemination in space, demonstrated by:   
 MRI 
 or a positive CSF and 2 or more MRI lesions 
consistent with MS 
 or further clinical attack involving different 
site 
 1 attack 
 2 or more objective clinical lesions 
Dissemination in time, demonstrated by:  
 MRI 
 or second clinical attack  
 1 attack 
 1 objective clinical lesion 
(monosymptomatic presentation) 
Dissemination in space demonstrated by:  
 MRI 
 or positive CSF and 2 or more MRI lesions 
consistent with MS 
and  
Dissemination in time demonstrated by:  
 MRI 
 or second clinical attack 
Insidious neurological progression  
suggestive of MS  
(primary progressive MS) 
Positive CSF  
and  
Dissemination in space demonstrated by:  
 MRI evidence of 9 or more T2 brain lesions 
 or 2 or more spinal cord lesions 
 or 4-8 brain and 1 spinal cord lesion 
 or positive VEP with 4-8 MRI lesions 
 or positive VEP with <4 brain lesions plus 1 
spinal cord lesion 
and  
Dissemination in time demonstrated by:  
 MRI 
 or continued progression for 1 year 
Table 1. 2001 McDonald diagnostic criteria for multiple sclerosis (from McDonald et al., 
2001; with permission) 
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Clinical Presentation Additional Data Needed 
 2 or more attacks (relapses; 
exacerbations) 1 
 2 or more objective clinical lesions or 
 Objective clinical evidence of 1 lesion 
with reasonable historical evidence of a 
prior attack 2
None3 
 2 or more attacks1 
 Objective clinical evidence of 1 lesion 
Dissemination in space, demonstrated by: 
 1 T2 lesion in at least 2 of 4 MS-typical 
regions of the CNS (periventricular, 
juxtacortical, infratentorial, or spinal 
cord) 4  
or 
 Await a further clinical attack1 
implicating a different CNS site 
 1 attack1   
 Objective clinical evidence of 2 or more 
lesions 
 
Dissemination in time, demonstrated by: 
 Simultaneous presence of 
asymptomatic gadolinium-enhancing 
and nonenhancing lesions at any time;  
or 
 A new T2 and/or gadolinium-
enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference 
to a baseline scan;  
or 
 Await a second clinical attack1 
 1 attack1  
 Objective clinical evidence of 1 lesion 
(clinically isolated syndrome) 
Dissemination in space and time, 
demonstrated by: 
For DIS: 
1 or more T2 lesion in at least 2 of 4 MS-
typical regions of the CNS (periventricular, 
juxtacortical, infratentorial, or spinal cord) 4  
or 
 Await a second clinical attack1 
implicating a different CNS site;  
and 
For DIT: 
 Simultaneous presence of 
asymptomatic gadolinium-enhancing 
and nonenhancing lesions at any time;  
or 
 A new T2 and/or gadolinium-
enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference 
to a baseline scan;  
or 
 Await a second clinical attack1 
www.intechopen.com
 
Neuroimaging in Multiple Sclerosis 
 
321 
Clinical Presentation Additional Data Needed 
Insidious neurological progression 
suggestive of MS (PPMS) 
 
1 year of disease progression 
(retrospectively or prospectively 
determined) plus 2 of 3 of the following 
criteria: 4 
 Evidence for DIS in the brain based on 
1 or more T2 lesions in the MS-
characteristic (periventricular, 
juxtacortical, or infratentorial) regions 
 Evidence for DIS in the spinal cord 
based on 2 or more T2 lesions in the 
cord 
 Positive CSF (isoelectric focusing 
evidence of oligoclonal bands and/or 
elevated IgG index) 
1 An attack is defined as patient-reported or objectively observed events typical of an acute 
inflammatory demyelinating event in the CNS, current or historical, with duration of at least 24 hours, 
in the absence of fever or infection.  
2 Clinical diagnosis based on objective clinical findings for 2 attacks is most secure. Historical evidence 
for 1 past attack can include events with symptoms and evolution characteristic for a prior 
inflammatory demyelinating episode; at least 1 attack, however, must be supported by objective 
findings. 
3 No additional tests are required. However, it is desirable that any diagnosis of MS be made with 
access to imaging based on these Criteria.  
4 Gadolinium-enhancing lesions are not required; symptomatic lesions are excluded from consideration 
in subjects with brainstem or spinal cord syndromes. 
Table 2. The 2010 McDonald Criteria for Diagnosis of MS (from Polman et al., 2011; with 
permission) 
2.1 Characteristic findings on conventional MRI techniques       
Hydrogen protons of water are highly abundant in our body. Conventional MRI measures 
alterations in tissue water content and dynamics by proton excitation, thus enabling 
visualization of edema, inflammation, demyelination and axonal damage in MS lesions. 
Conventional MRI techniques include T2-weighted, fast fluid-attenuated inversion recovery 
(FLAIR), and T1-weighted imaging with and without gadolinium (Gd) administration. 
In routine evaluation of patients with suspected or known MS, the most useful image 
acquisition clinical protocols for cMRI are axial dual spin-echo or single late echo T2-
weighted imaging, axial and sagittal FLAIR, and pre- and post-gadolinium (Gd)-enhanced 
axial spin-echo T1-weighted imaging (Bakshi et al., 2004). On cMRI scans, detected MS 
lesions are presented as hyperintensities on T2- weighted images, hypointensities on T1-
weighted images, and Gd-enhancing foci on postcontrast images. 
2.1.1 T2-weighted imaging    
T2-weighted MRI is sensitive in detecting white matter lesions. In T2-weighted images, MS 
lesions appear as bright areas against a gray or more neutral background; this hyperintesity 
reflects an increase in water content and thus is not specific for the underlying pathology. 
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The T2 hyperintense lesions represent processes ranging from edema and inflammation to 
demyelination, remyelination, Wallerian degeneration, axonal loss and gliosis (Fillipi & 
Agosta, 2009; Markovic-Plese & McFarland, 2001). Once detected, a lesion typically persists 
in the T2 hyperintense stage for many years. The techniques that are commonly used for the 
identification of T2 hyperintense lesions are conventional spin echo, fast spin echo, and 
fluid-attenuated inversion recovery (FLAIR) (Filippi et al., 2006). FLAIR imaging is a 
technique that suppresses the CSF signal, being more sensitive to periventricular and 
cortical/juxtacortical lesions and less sensitive to infratentorial lesions than T2-weighted 
MRI (Bakshi et al., 2001). 
Given the lack of specificity of hyperintensities on T2-weighted MRI, lesion location and 
morphology plays a prominent role in distinguishing demyelinating lesions from the 
common and incidental presence of non-specific white-matter abnormalities, microvascular 
ischemia, or enlarged perivascular spaces (Fig. 1). MS lesions are primarily found in white 
matter but also in gray matter and usually affect the periventricular regions, corpus 
callosum, juxtacortical gray-white matter junction in the white matter, and infratentorial 
brain regions (brain stem, middle cerebellar peduncles and cerebellar white matter in the 
posterior fossa) (Bakshi et al., 2004; Barkhof et al., 1997). In some cases, direct involvement of 
the cerebral cortex also may be apparent (Bakshi et al., 2001). Corpus callosum is commonly 
affected in MS due to the large amount of myelinated fibres it contains. Callosal 
demyelinating lesions are usually multiple, small, nodular and characteristically involve 
callosal-septal interface. Infratentorial lesions are considered specific for multiple sclerosis 
and are typically located at the surface of the pons, the base of the fourth ventricle, and in 
the intra-axial trigeminal tract. It is important to note however that they can also be found in 
small-vessel disorder, with characteristic involvement of the central part of the pons (Kwa et 
al., 1997). Demyelinating lesions are larger (> 3mm) than punctuate non-specific white 
matter abnormalities associated with migraine and microvascular ischemia.  
Characteristically, they have an ovoid shape and appear perpendicular to the long axis of 
the ventricles in the axial plane. These typical MRI findings reflect the histopathological 
findings in multiple sclerosis. The periventricular lesions, especially in the corpus callosum, 
and the ovoid abnormalities with extensions (Dawson’ fingers) into the adjacent white 
matter correlate with the perivenular distribution of multiple sclerosis plaques  (Gean-
Marton et al., 1991). 
Between 50% and 90% of MS patients show hyperintense T2 lesions in the spinal cord, more 
frequently located in the cervical and the thoracic area (Lycklama et al., 2003; Agosta & 
Filippi, 2007). Cord lesions are usually located peripherally, occupy less than one half of the 
cord cross-sectional area and rarely involve more than two contiguous vertebral segments in 
length. Acute lesions may be associated with cord swelling. The presence of characteristic 
spinal cord abnormalities on MRI increases both sensitivity and specificity to the diagnosis 
of MS (Fillipi & Agosta, 2009).  
In 50–70% of patients presenting with CIS clinically silent MRI lesions suggestive of MS are 
found. The extent of T2 lesions on brain MRI in CIS patients can predict the future risk of 
MS. The majority of CIS patients with T2 abnormalities (56–88%), develop clinically definite 
MS (CDMS) after prolonged (7–14 years) follow-up, whereas a minority of those with 
normal MRI (approximately 20%) have a risk for conversion to definite MS (Barkoff et al., 
1997; Tintoré et al, 2006). Moreover, brain T2 hyperintense lesion load early in the clinical 
course of MS is also a predictor of long-term disability (Di Filippo et al., 2010).  
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(a) Axial FLAIR image showing typical 
ovoid periventricular hyperintense MS 
lesions 
 
(b) Axial FLAIR scan revealing 
juxtacortical lesions 
  
(c) Sagittal T2-weighted image 
demonstrating lesions in the corpus 
callosum and periventricular white matter  
with  characteristic extensions (Dawson’s 
fingers) 
 
(d) Axial T2 scan showing characteristic 
infratentorial involvement 
Fig. 1. (a-d). Axial and sagittal FLAIR and T2 images showing common sites of MS 
involvement. 
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2.1.2 T1-weighted imaging      
On noncontrast T1-weighted images (T1-WI), most T2 brain lesions are isointense in white 
matter; however, some are hypointense (van Walderveen et al., 1998). These hypointense 
lesions may be acute and reversible within 6 months or chronic (referred to as black holes) 
(Fig. 2). The acute T1 hypointense lesions are likely to represent oedema and inflammation 
or demyelination with subsequent remyelination whereas the chronic ones severe 
demyelination and irreversible axonal loss (Bagnato et al., 2003; Brex et al., 2000; Filippi et 
al., 2001; Van Walderveen et al., 1998). The percentage of newly formed hypointense lesions 
that do revert to isointensity varies between 20 and 60% (van Waesberghe et al., 1998). 
Larger size of the lesions, longer duration of Gd-enhancement and ring enhancement are 
associated with the development of persistent T1- hypointense black holes (Mineboo et al., 
2005). T1 hypointense lesions correlate better with clinical evolution and disability than T2 
lesions and therefore may be a useful biomarker of progressive tissue damage in established 
MS (Truyen et al., 1996). By contrast to chronic cerebral lesions, chronic spinal cord lesions 
are isointense on T1-weighted images (Fillipi & Agosta, 2009). 
 
  
 a) Axial T1-weighted noncontrast MRI 
showing a chronic hypointensity in the 
right frontal periventricular white matter 
(b) Corresponding hyperintensity on 
FLAIR scan. 
Fig. 2. (a-b) A chronic black hole in a 32-year-old woman with relapsing-remitting MS 
2.1.3 Postcontrast T1-weighted imaging     
On T1-weighted scans, gadolinium injection enables detection of lesions with active 
inflammation and blood–brain barrier (BBB) disruption, as it is normally excluded from the 
brain by the BBB. Gd-enhancing lesions on T1-WI typically correspond to areas of high 
signal intensity on T2-WI and, in some instances, low signal intensity on T1-WI that stem 
from edema and demyelination (Zivadinov & Cox, 2007). There are various patterns of 
gadolinium enhancement in MS lesions that usually persists for 2 – 6 weeks (Cotton et al., 
2003): homogeneous, heterogeneous, punctuate, ring, open ring enhancing and tumor-like 
(Fig. 3). Among them, the incomplete or open-ring morphology (Fig. 3a) is particularly 
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characteristic of MS lesions (Masdeu et al., 1996). Compared with homogeneously 
enhancing plaques, ring-enhancing lesions are larger and have a shorter duration of 
enhancement (Minneboo et al., 2005). Concentric ring enhancing lesions with central 
contrast pallor appear in areas of heightened local inflammation (Rovira et al., 1999). 
Results of serial MRI studies demonstrate that enhancement usually precedes or 
accompanies the appearance of most new lesions on T2-WI in all disease subtypes, even in 
primary-progressive MS (Molyneux et al., 2001). However, Gd- enhancement is more 
commonly seen in patients with relapsing-remitting (RRMS) than in patients with primary 
or secondary progressive MS (Thompson et al., 2000) and is considered sensitive to disease 
activity and predictive of future clinical relapses. Enhancing lesions do not correlate with 
long-term disability (Kappos et al., 1999), with the exception of ring-enhancing plaques that 
are usually suggestive of a more aggressive form of MS. Ring-enhancement is associated 
with severe tissue damage, persisting hypointense T1 lesions and subsequent development 
of cerebral atrophy (Morgen et al., 2001; Bagnato et al., 2003; Minneboo et al., 2005;). 
Enhancing lesions are less frequently seen in the cord (Fig. 3b)  than in the brain (Filippi & 
Agosta, 2009).  
 
  
(a) Puctuate, homogeneous, and ring 
enhancing brain lesions 
(b) Spinal enhancing lesion 
Fig. 3. Characteristic patterns of enhancement on T1-weighted scans 
2.2 Conventional MRI characteristics suggesting alternative diagnoses      
Although existing diagnostic criteria for multiple sclerosis have emphasized that alternative 
explanation for the clinical presentation must be considered and excluded before a diagnosis 
of MS can be made, they mainly focus on early diagnosis of patients presenting with a first 
clinical episode suggestive of MS (e.g., unilateral optic neuritis, internuclear 
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ophthalmoplegia, partial myelopathy). Incorporated data from magnetic resonance imaging 
are used as prognostic for the subsequent development of clinically definite MS, rather than 
diagnostic (McDonald et al., 2001; Polman et al., 2005, 2011). However, the increased 
availability of MRI scanners and the sensitivity of this technique in showing asymptomatic 
lesions of multiple sclerosis, have revealed difficulties in the application of existing MRI 
criteria, the most common of which is the incidental presence of non-specific white-matter 
abnormalities on MRI scans of patients who have headache, vertigo or a variety of other 
common disorders and the inability to differentiate these lesions from those that are typical 
for MS. Recognition of MRI features that are not suggestive of MS or even suggestive of 
another disorder is essential, as it underlines the need for extensive evaluation of patients 
presenting with such abnormalities in order to avoid misdiagnosis. 
A set of MRI signs (red flags), which suggest alternative conditions that mimic MS has been 
defined by the European MAGNIMS group (Charil et al., 2006). It is important to note 
however that these red flags (Table 3) should be considered in the appropriate clinical 
context in order to exclude the most common alternatives (Miller et al., 2008).  
The distribution of lesions is an important parameter that should be considered in the 
differential diagnosis of demyelinating lesions. In hypoxic-ischemic diseases lesions follow 
arterial anatomy, such as borderzone or watershed lesions, lacunes, multifocal basal ganglia 
lesions and cortical infarcts whereas in multiple sclerosis are perivenular (Enzinger et al., 
2006). Moreover, the corpus callosum is not usually involved in hypoxic-ischemic diseases, 
due to its rich blood supply; on the contrary, this is commonly affected in MS due to the 
large amount of myelinated fibres it contains, with characteristic involvement of callosal-
septal interface (Gean-Marton et al., 1991).  Infratentorial lesions are uncommon in small-
vessel disorder, but when they occur they are typically located in the central part of the pons 
(Kwa et al., 1997). The predominance of lesions located at the cortical or subcortical areas, as 
well as the coexistence of brain infarcts, calcification, or haemorrhages are usually 
suggestive of systemic immune mediated diseases with CNS involvement, small-vessel 
vasculitides, or antiphospholipid antibody syndrome (either primary or secondary to 
systemic immune-mediated diseases). In these disorders, enhancing lesions and T1 black 
holes are much less common than in multiple sclerosis (Theodoridou & Settas, 2008). 
Extensive brainstem and basal ganglia lesions that can be associated with swelling and 
enhancement in the acute phase and that can shrink or disappear at follow-up may be a 
manifestation of Behçet’s disease (Lee et al., 2001). Bilateral and symmetric white-matter 
lesions are other important features against the diagnosis of multiple sclerosis. Although 
adult forms of leucodystrophies, such as adrenoleucodystrophy, metachromatic 
leucodystrophy, and Krabbe disease may have a MRI pattern resembling that of MS, white-
matter lesions tend to be bilateral and symmetric (Barkhof & Scheltens, 2002).  Diffuse and 
confluent symmetrical T2-weighted hyperintensities in the deep and periventricular white 
matter with characteristic involvement of the external capsules and temporal poles are 
considered highly specific for cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leucoencephalopathy (CADASIL) and may distinguish it from MS (Andreadou 
et al., 2008; O’Sullivan et al., 2001; Singhal et al., 2005). Moreover, the cortex, corpus 
callosum and infratentorial regions (except the pons) are rarely affected in CADASIL 
(Singhal et al., 2005). Furthermore, the presence of multiple microhaemorrhagic foci, which 
can be seen on gradient-echo images, is another characteristic feature of CADASIL 
(Dichgans et al., 2002). Another feature pointing against the diagnosis of MS is significant 
asymmetry of the white-matter abnormalities, which is usually suggestive of ipsilateral 
carotid disease (Andreadou et al., 2010; Barkhof & Scheltens, 2002). 
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Brain white matter 
Normal  
Lesions 
  Morphology 
  Large lesions  
 
 
 
 
  Poorly defined lesion margins  
  Absent or rare Dawson fingers 
  Absent MRI activity at follow-up  
  Isolated lesions with ring enhancement (often complete)  
  Mass effect  
  Large lesions with absent or rare mass effect  
  Multiple bilateral microhaemorrhagic foci  
  Haemorrhages  
  Infarcts  
  Distribution 
  Substantially asymmetric distribution of lesions  
  Extensive and bilateral periventricular  abnormalities in
  isolation 
  Symmetrically distributed lesions  
  Absent or rare corpus callosum and periventricular    
  lesions 
  Frequent sparing of corpus callosum and    cerebellum 
  Lesions in the centre of corpus callosum,    sparing the
  periphery  
  T2-hyperintensity of the temporal pole, U-   fibres at the
  vertex, external capsule and insular regions 
  Predominance of lesions at the cortical/subcortical  
  junction  
  Diffuse WM involvement  
 
  Cerebral venous sinus thrombosis  
  Large and infiltrating brainstem lesions  
  Pontine lacunar infarcts 
  Anterior temporal and inferior frontal lobe involvement, 
  associated with enhancement or mass effect 
  Multifocal, asymmetrical lesions starting in a    
  juxtacortical location and progressively enlarging  
  Pattern of enhancement 
 
  Simultaneous enhancement of all lesions  
Disease  
NMO (absent or few lesions), ATM  
 
 
AMS (sometimes confluent and 
perilesional oedema),  
BCS (concentric whorls of 
alternating rings of enhancement), 
PACNS (with mass effect)  
ADEM 
ADEM 
ADEM 
Abscesses 
Abscesses 
PML 
CADASIL, SVD 
PACNS 
SID, PACNS, SVD  
 
Ipsilateral carotid disease 
B12D, ACD 
 
ADEM, AFL  
 
ADEM  
SVD, CADASIL  
Susac’s syndrome  
 
CADASIL 
 
SID 
 
NBD, encephalitis (HIVE), SVD, 
CADASIL 
NBD 
NBD 
CADASIL, SVD 
Encephalitis (HSE) 
 
PML 
 
 
 
ADEM, PACNS, sarcoidosis 
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  Punctiform parenchymal enhancement 
 
Cortical grey matter 
Cortical/subcortical lesions crossing vascular territories 
Prevalent involvement versus white matter  
Infiltrating lesions that do not remain in grey or white 
matter boundaries 
Deep grey matter 
Bilateral lesions  
 
Lacunar infarcts  
T1-hyperintensity of the pulvinar  
Multiple discrete lesions in the basal ganglia and 
thalamus  
Large and infiltrating basal ganglia lesions  
Infiltrating lesions without respecting grey-matter or 
white-matter boundaries 
T2-hyperintense lesions in the dentate nuclei  
PACNS, sarcoidosis, NBD  
 
 
MELAS 
Encephalitis 
Abscesses 
 
 
ADEM (at the grey–white-matter 
junction), CADASIL 
CADASIL, SVD 
FD 
Susac’s syndrome  
 
NBD 
Abscesses 
 
AFL (CTX) 
 
Spinal cord 
Large and swelling lesions  
 
 
Diffuse abnormalities in the posterior columns  
Other 
Absence of optic-nerve lesions  
Hydrocephalus  
Dilation of Virchow-Robin spaces  
Meningeal enhancement  
 
 
Regional atrophy  
 
No “occult” changes in the NAWM  
 
Diffuse lactate increase on brain MRS  
 
 
NMO (with corresponding T1 
hypointensity), ADEM, ATM, 
Sjogren’s syndrome 
B12D, ACD 
 
PML 
Sarcoidosis 
HHC, PACNS 
Susac’s syndrome, PACNS, NBD, 
meningitis, Lyme disease, 
sarcoidosis  
HHC (hippocampus and 
amygdala), NBD (brainstem) 
NMO, Lyme disease, SID (except 
in NSLE) 
MELAS 
ACD=acquired copper deficiency. ADEM=acute disseminated encephalomyelitis. AFL=adult forms of 
leucoencephalopathies. AMS=acute multiple sclerosis (Marburg type). ATM=acute transverse myelitis. 
B12D=vitamin B12 deficiency. BCS=Balo’s concentric sclerosis. CTX=cerebrotendinous xanthomatosis. 
FD=Fabry’s disease. HHC=Hyperhomocysteinaemia. HIVE=HIV encephalitis. HSE=herpes simplex 
encephalitis. MELAS=mitochondrial encephalopathy with lactic acidosis and stroke-like episodes. 
MRS=magnetic-resonance spectroscopy. NAWM=normal-appearing white matter. NBD=Behçet’s 
disease with CNS involvement. NMO=neuromyelitis optica. NSLE= neuropsychiatric systemic lupus 
erythematosus. PACNS=primary angiitis of the CNS. PML=progressive multifocal 
leucoencephalopathy. SID=systemic immune-mediated diseases. SVD=small-vessel disease. 
Table 3. MRI characteristics suggestive of alternative conditions that mimic MS (adapted 
from Charil et al., 2006; with permission). 
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By contrast to MS where MRI-detectable spinal cord lesions can be found in the majority of 
patients with established disease (Lycklama et al., 2003; Agosta and Filippi, 2007), spinal 
cord abnormalities are not observed in patients with hypoxic-ischemic disease and are 
rarely reported in other immune-mediated disorders (Bot et al, 2002), and progressive 
multifocal leucoencephalopathy (Yousry et al., 2006). Another characteristic pointing against 
the diagnosis of MS is the complete disappearance of spinal cord lesions in systemic 
immune-mediated diseases after steroid or immunosuppressive treatment (Rovaris et al., 
2000). Moreover, incidental spinal cord hyperintense foci do not occur with ageing 
(Lycklama et al., 2003). Therefore, cord MRI is helpful in patients with normal or equivocal 
brain MRI and in those more than 50 years old (Agosta & Filippi, 2007). Longitudinally 
extensive spinal cord involvement (usually three or more segments), affecting primarily the 
central part of the spinal cord on axial sections, is typically seen in neuromyelitis optica. 
Moreover, NMO myelopathy is often associated with swelling and T1 hypointensity in the 
acute and chronic stages (de Seze et al., 2002; Wingerchuk et al., 2007). 
The pattern of enhancement is another useful distinctive characteristic. Simultaneous 
enhancement of multiple white-matter lesions is usually observed in neurosarcoidosis and 
primary angiitis of the CNS (PACNS). Moreover, meningeal enhancement should raise the 
suspicion of PACNS, neurosarcoidosis or neuroBehçet’s disease (Campi et al., 2001; Zajicek 
et al., 1999). 
It is important to note that when these MRI features ‘not suggestive’ of multiple sclerosis are 
used along with the existing MS diagnostic criteria, they minimize the chance of false 
positive diagnoses and facilitate the correct diagnosis of other disorders. Therefore, it is 
suggested to be taken into account in the diagnostic work-up of patients suspected of having 
MS. In the presence of at least one MRI ‘red flag’, appropriate additional tests should be 
performed. However, in cases of equivocal findings, follow-up with repeated imaging will 
be needed to establish a firm diagnosis (Charil et al., 2006)  
3. MRI and disease progression    
Recognition of the neurodegenerative aspects of MS has rendered the development of 
techniques to measure disease progression essential. Since conventional MRI is sensitive in 
detecting disease activity, it has routinely been used to ameliorate not only the accuracy of 
multiple sclerosis diagnosis but also the prognosis. Conventional MRI assessment of lesions 
on non-contrast T1-weighted and T2-weighted scans, and on gadolinium-enhanced T1-
weighted images is now routinely used to monitor the disease course and detect therapeutic 
effects (Zivadinov & Leist, 2005). However, measures like the lesion volume and the number 
of gadolinium-enhancing and T2 lesions, are weakly associated with the clinical status and 
have insufficient sensitivity and specificity to reveal the extent of histopathological changes 
occurring in MS. Persistent T1 hypointense lesions can predict development of disability 
better than the previously mentioned lesion-based MRI measures (Zivadinov & Leist, 2005) 
as they are mainly associated with more advanced pathological processes of the disease, i.e. 
axonal loss, Wallerian degeneration and gliotic changes (Bakshi et al., 2004; Stevenson et al., 
2004). Moreover, brain and spinal cord atrophy have been shown to be powerful predictors 
of clinical impairment and disease progression. Additionally, newer nonconventional MRI 
techniques that become increasingly available hold significant promise to improve 
monitoring of MS. Accumulating evidence suggests that metrics derived from non-cMRI 
techniques correlate better with disability compared to conventional measures. 
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3.1 Detection of subclinical disease activity          
Conventional MRI can be used as a valuable tool for the assessment of disease progression, 
as it provides objective and sensitive measures of MS activity. In patients with RRMS and 
SPMS, disease activity is detected 5–10 times more frequently on cMRI scans than with 
clinical assessment of relapses (Filippi & Agosta, 2010). Despite the sensitivity of T2-
weighted images to reveal disease activity and lesions over time (Molyneux et al., 1998), no 
significant correlation between MRI findings and clinical progression has been 
demonstrated, except in patients with very early disease (Rovaris et al., 2003). Indeed, both 
brain T2 hyperintense lesion load early in the clinical course and early progression of T2 
burden of MS have been associated with the development of long-term disability (Brex et al., 
2002). However, T2 lesion load measurement is not appropriate for the assessment of the 
advanced stages of the disease (Li et al., 2006). Although differences in T2 lesion load among 
different MS phenotypes have been consistently reported, being higher in SPMS in 
comparison to benign MS, RRMS, and PPMS, no significant relationship between T2 lesion 
load and disability has been demonstrated (Filippi & Agosta, 2010). 
Gd enhancement occurs in almost all new lesions in patients with RRMS or SPMS and can 
be sometimes detected even before the onset of clinical symptoms (Filippi & Agosta, 2010). 
The number of enhancing lesions increases shortly before and during clinical relapses and 
predicts subsequent MRI activity (Molyneux et al., 1998, Kappos et al., 1999). The burden of 
MRI activity has been shown to be associated with the subtype of the disease, being higher 
in RRMS and SPMS in comparison with PPMS and BMS (Kappos et al., 1999). Moreover, 
patients with SPMS and severe disability show a lower incidence of enhancing lesions when 
compared to those with mildly disabling RRMS (Filippi et al., 1997). However, a moderate 
correlation has been demonstrated between the degree of clinical disability and the mean 
frequency of enhancing lesions in patients with RRMS and SPMS (Filippi & Agosta, 2010). 
T1 black holes and CNS atrophy are useful markers of progressive tissue damage and 
clinical evolution in established MS. In patients with either RRMS or SPMS, the increase in 
T1 lesion volume (LV) over time correlates significantly with progressive cerebral atrophy 
and the change in EDSS score (Sailer et al., 2001; Truyen et al., 1996). Moreover, in patients 
with CIS, baseline T1 hypointense lesion number and volume are strong predictors of the 
severity of executive dysfunction (Summers et al., 2008). 
3.2 Detection of brain and spinal cord atrophy          
Since the initial MRI studies in MS, marked atrophy of the brain has been found to be an 
important feature of the advanced stages of the disease (Filippi & Agosta, 2010). 
Subsequently, it was recognised as an early phenomenon that progresses over the disease 
course. Thus, conventional MRI has been used to measure atrophy of the brain tissue, whole 
or segmented in white matter (WM) and gray matter (GM). Cerebral volume loss is 
associated with changes in normal appearing white matter and grey matter (Ge et al., 2000; 
Horakova et al., 2009). It occurs in all MS subtypes (even in CIS) with a rate of 0.5-1% per 
year and is closely related to disability (Anderson et al., 2006; Bermel & Bakshi, 2006). 
Moreover, brain atrophy develops in different structures in the different clinical phenotypes 
of the disease: ventricular enlargement is predominant in RRMS, whereas cortical atrophy is 
more pronounced in the progressive forms of the disease (Pagani et al., 2005). The most 
atrophic cortical regions have been consistently found to be the frontal, temporal and 
parietal lobes (Filippi & Agosta, 2010). GM atrophy rate has been found to increase with 
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disease progression, whereas WM atrophy rate has been reported to remain constant (Fisher 
et al., 2008). Atrophy of the deep gray matter has been also observed in MS, especially in the 
posterior basal ganglia and the thalamic regions (Bermel & Bakshi, 2006; Carone et al., 2006; 
Filippi & Agosta, 2010; Henry et al., 2008). Measurement of atrophy in selected pathways, 
such as the corpus callosum and the corticospinal tract, may also improve the in vivo 
monitoring of MS progression (Martola et al., 2007). In addition, spinal cord atrophy, more 
pronounced in the progressive forms of MS, has been reported (Rovaris et al., 2001). It 
should be mentioned, however, that reduction of the cervical cord size can be observed in 
the early stages of MS (Brex et al., 2001). CNS atrophy reflects the destructive component of 
the MS disease process and contributes to irreversible neurological impairment.  
Recent advances in volumetric MRI with the use of parallel imaging techniques may 
improve the use of atrophy metrics as outcome measures in clinical trials of MS therapies. It 
should be mentioned however, that the anti-inflammatory effect of MS treatments can 
reduce brain volume (a phenomenon called pseudoatrophy effect), and consequently affect 
atrophy measurements (Zivadinov et al., 2008). Advances in neuroimaging may help 
separate true atrophy from pseudoatrophy with the use of methods that can distinguish 
axonal loss from transient changes in water content. 
3.3 MRI in disease management and evaluation of treatment outcomes          
Since MRI provides information essential in monitoring disease activity and severity of 
multiple sclerosis, it is a critical component of disease management. In addition to the 
relapse rate and progression on EDSS, MRI variables play an essential role in determining 
the short and long-term effects of MS treatments, since the approval of the first therapy for 
MS by the Food and Drug Administration in 1993 (Rovaris, 2008; Bates, 2011; Freedman, 
2011). Short-term and long-term clinical trial results have indicated that currently available 
disease-modifying therapies (DMTs) are effective in reducing MRI disease activity (Bates, 
2011; Freedman, 2011). Moreover, reduction in MRI-detected lesion burden is used as 
supportive to the clinical findings to show reduction in disease activity. Brain MRI activity is 
determined as the number of new or enlarging T2-hyperintense lesions and Gd-enhancing 
lesions, whereas the MRI burden of the disease includes the T2-lesion volume and the T1-
hypointense LV. 
Accumulating evidence suggests that MRI-derived metrics could be used to define 
treatment options and strategies in individual patients with MS (Beck et al., 2002; Rudick et 
al., 2004). In RRMS, the accumulation of two or more new T2-hyperintense lesions during a 
two-year period has been demonstrated to predict poor treatment response more reliably 
than the persistence of clinical relapses and the presence of enhancing lesions (Rudick et al., 
2004). In CIS, the subgroup of patients with enhancing lesions at baseline showed a trend for 
greater treatment benefit than patients without (Beck et al., 2002). However, only the 
integration of clinical and MRI data can be considered a reliable approach for the work-up 
of patients receiving disease-modifying treatments. 
Recently, clinical trials have incorporated cerebral volume measurement to determine the 
efficacy of novel treatments (Bermel & Bakshi, 2006). However, the current inability to 
separate true atrophy from pseudoatrophy limits the use of atrophy measures at present. 
Advances in MRI technology might contribute to a better correlation between clinical and 
MRI findings, and thus provide relevant information to improve prognosis and predict 
therapeutic response. 
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4. Nonconventional MRI techniques           
Conventional MRI is unable to disclose the extent of the damage because of its limited 
sensitivity to structural changes outside the focal lesions and its lack of specificity to the 
heterogeneous features of the disease. The hyperintense lesions  on T2-weighted images 
represent nonspecific tissue alterations as they reflect changes in water content caused by a 
variety of processes including edema, inflammation, demyelination, remyelination, 
Wallerian degeneration, gliosis and axonal loss. Furthermore, neurological impairment of 
patients with MS is poorly associated with the lesion load observed on conventional MRI 
scans (Filippi & Agosta, 2010). During the past decade, other nonconventional MRI 
techniques-including proton MR spectroscopy, magnetization transfer MRI, diffusion tensor 
MRI, double inversion recovery sequences, high-field and ultrahigh-field MR imaging, 
techniques employing cellular MR contrast agents, and functional MRI-have been 
developed to overcome these limitations, improve the sensitivity and specificity in the 
detection of MS lesions and characterize and quantify the heterogeneous pathological 
substrates of the disease. Issues encountered in emerging clinical application of these 
methods will be addressed.  
4.1 Magnetic resonance spectroscopy     
Conventional MRI describes the physical characteristics of a region of tissue relative to 
surrounding regions by measuring alterations in tissue water content and dynamics by 
proton excitation. Proton MR Spectroscopy (1H-MRS) is a non invasive method that depicts 
the chemical properties of a region of brain tissue by investigating other proton-containing 
cellular metabolites. It provides information on tissue metabolism and function of a selected 
brain area volume relative to surrounding regions. Therefore it could be used to study 
biochemical changes occurring in lesions and normal appearing white matter over the 
course of MS (De Stefano et al., 2007).  1H-MRS could also be used as a diagnostic tool, 
although it has not yet moved to clinical practice. 
Various compounds can be detected using 1H-MRS. At long echo times four major 
resonance peaks are revealed from (a) choline-containing phospholipids (Cho), (b) creatine 
and phospho- creatine (Cr), (c) N-acetyl-aspartate (NAA), and (d) lactate (Lac) methylgroup. 
NAA, normally present in axons and neurons, reflects neuronal/axonal integrity and 
therefore appears to be a sensitive biomarker of disease progression (Narayana, 2005). A 
decline in NAA levels in MS, with correlation with disability, has been shown in several 
studies. Reduced NAA was observed in lesions, cortical GM and NAWM in early RRMS 
(Kapeller et al., 2001; Chard et al., 2002). Decrease in NAA levels in chronic WM lesions has 
been reported in RRMS, SP and PPMS (Davie et al., 1997). Moreover, chronic lesions have 
higher NAA signal intensities in patients with BMS than those in patients with SPMS, 
indicating a more efficient tissue integrity recovery in patients with less severe disability (De 
Stefano et al., 2007). Transient changes in NAA levels in acute MS plaques have been also 
reported (Narayama et al, 1998). Decreases in NAA concentrations are also known to occur 
in the NAWM of MS patients (Caramanos et al., 2005). Furthermore, significant reduction in 
whole-brain NAA levels was found, more pronounced in older than younger patients 
(Gonen et al., 2000).  
Cho and Lac reflect cell membrane metabolism. Increases in these metabolites are 
considered as chemical correlates of acute inflammatory or demyelinating changes. Indeed, 
increases in Cho and Lac resonance intensities have been found in acute MS lesions (Davie 
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et al., 1994; De Stefano et al., 1995). In large, acute demyelinating lesions, decreases of Cr 
have also been seen (De Stefano et al., 1995).  
1H-MRS studies with shorter echo times can detect additional metabolites, such as lipids and 
myoinositol (mI), which are also regarded as markers of progressing myelin damage. 
Increase of levels of myoinositol, which is mainly localised in astrocytes, has been shown in 
early MS (Capeller et al., 2001; De Stefano et al., 1995) and also in chronic lesions, indicating 
neuronal injury and ongoing astrogliosis (Srinivasan et al., 2005). Amino acids acting as 
neurotransmitters, such as glutamate, glutamine, and GABA (γ-aminobutyric acid), can also 
be measured. Glutamate levels were found to be increased in acute lesions (Srinivasan et al., 
2005). A reduced concentration of glutamate and glutamine in the cortical GM of patients 
with PPMS has been found (Sastre-Garriga et al., 2005), which was significantly correlated 
with the EDSS score. Recently, the concentration of glutathione, a marker of oxidative status, 
was measured by 1H-MRS at 7.0 T and was found decreased in the NAWM and gray matter 
of MS patients compared to healthy controls (Srinivasan et al., 2010). 
MRS may provide insight into MS pathogenesis, evaluate the severity of MS and follow 
disease evolution and therefore is becoming a useful tool in the understanding of the 
disease. Moreover, MRS measures of brain metabolites seem to be better predictors of 
clinical disability than is conventional MRI. 
4.2 Magnetization transfer imaging   
Magnetization transfer (MT) is a physical phenomenon in which protons of two or more 
environments with different magnetic resonance properties exchange magnetization. MT 
MRI measures quantitatively the continuous exchange of magnetization in the brain tissue 
between macromolecular bound protons (i.e. protons associated with myelin, cell 
membranes and proteins) and protons in adjacent free water molecules, thus allowing the 
calculation of an index, the MT ratio (MTR). Diminution of this index denotes a decreased 
capacity of the bound protons to exchange magnetization with the surrounding ‘‘free’’ 
water (Filippi & Agosta, 2007). The reduction of MTR values in focal lesions is considered as 
a marker of the extent of tissue damage, primarily associated with demyelination (Schmierer 
et al., 2004; van Buchem et al., 1996). The relative specificity of MTR to myelin density has 
been demonstrated by post-mortem imaging and histopathological studies that did not 
reveal any significant association with axonal density or gliosis (Schmierer et al., 2004).  
Voxel-based analysis of MTR changes can provide indirect information about demyelination 
and remyelination in MS lesions (Chen et al., 2007). Changes of MTR of individual lesion 
voxels, as well as the mean normalized MTR over all lesion voxels during and after contrast 
enhancement have been reported (Chen et al., 2008). The mean normalized MTR of Gd-
enhancing lesions was significantly decreased at the time of lesion enhancement, partially 
recovered over the subsequent four months, and then appeared to stabilize. Moreover, 
enhancing lesions were found to have different MTR values, according to their size, pattern, 
and duration of enhancement. Specifically, MTR was lower in ring-enhancing lesions than in 
homogeneously enhancing lesions (Silver et al., 1998) and in lesions with longer duration of 
enhancement (Filippi et al., 1998a), suggesting more severe demyelination. Furthermore, 
evolution of the mean normalized MTR of individual lesions shows considerable 
heterogeneity ranging from partial recovery or stability that suggest remyelination, to 
decline over time that suggests ongoing demyelination (Chen et al., 2008). 
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In addition to increased specificity, MTI may also offer increased sensitivity for studies of 
MS. Focal changes in magnetization transfer were reported to precede the appearance of 
gadolinium-enhancing lesions (Filippi et al., 1998b). Moreover, microscopic damage in 
normal-appearing brain tissues was shown on MTI before the development of T2 lesions on 
cMRI scans (Laule et al., 2003).  
Decreased MTR has also been found in normal appearing brain tissue (NABT), in both gray 
(Ge et al., 2001; Dehmeshki et al., 2003) and white matter (Santos et al., 2002), of patients 
with established MS. These abnormalities are more pronounced in patients with the 
progressive forms of MS and tend to worsen over time (Filippi & Rocca, 2007). Moreover, 
reduced NABT MTR has been found in patients at presentation with CIS, with significant 
prognostic value for the subsequent evolution to clinically definite MS (Miller et al., 2005). 
NAWM and NAGM MTR abnormalities have been found to correlate with clinical disability 
(Ge et al., 2001; Santos et al., 2002) and cognitive impairment (Ranjeva et al., 2005). 
MTI metrics have several limitations that include lack of specificity to the various MS 
pathological substrates and lack of standard magnetisation transfer data acquisition 
protocols across different scanners (Horsfield et al., 2003). Improvement of the 
quantification and specificity of MTI with the use of new analysis methods (Chen et al., 
2008) may render this technique a reliable tool not only for studies of disease evolution, but 
also for diagnostic purposes in every day clinical practice.  
4.3 Diffusion weighted and diffusion tensor imaging   
Diffusion weighted (DWI) and diffusion tensor imaging (DTI) provide information about 
the tissue fibers by measuring the motion of tissue water molecules in vivo (Rovaris et al., 
2005). The mobility of water molecules is diminished in highly organized tissue, like white 
and gray matter, and consequently, the apparent diffusion coefficient (ADC) is lower in 
those tissues than in free water. Pathological processes that alter tissue organization can 
result in abnormal water motion, thus modifying ADC values. Tissue damage in MS, mainly 
demyelination and axonal degeneration, results in abnormal water motion, and therefore in 
alteration of the ADC values. Diffusion abnormalities may precede Gd-enhancement in 
hyperacute MS lesions.  
Diffusion tensor imaging (DTI) is a valuable technique based on the fact that diffusion of 
water molecules within white matter is much greater along the fibres than across them. The 
diffusion tensor is a mathematical description of the magnitude and predominant direction 
of water molecules movement (anisotropy) in the three-dimensional space. As the diffusion 
ellipsoid provides a description of the diffusion tensor, the individual components of the 
diffusion ellipsoid (called eigenvalues) can also be assessed separately. These components 
are the longitudinal or axial diffusivity (LD or AD), which is the principal eigenvalue of the 
DT, and the transverse or radial diffusivity (TD or RD) that is the average of the second and 
third eigenvalues of the DT. Quantitative DTI parameters, such as the fractional anisotropy 
(FA), which is a normalized measure of the degree of anisotropy, the mean diffusivity (MD), 
that is the averaged diffusion for detecting WM alterations, and the longitudinal and 
transverse diffusivities of the diffusion tensor are considered valuable tools in the 
assessment of focal and widespread white matter tissue damage in patients with MS. FA 
was found to be decreased (Werring et al., 1999) whereas MD was consistently shown to be 
increased in MS plaques as well as in normal appearing white matter of MS patients (Lowe 
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et al., 2006). However, FA values have been found to be increased in intracortical MS 
lesions, possibly reflecting intralesional loss of dendrites and activation of microglia 
(Poonawalla et al., 2008). Transverse diffusivity, which refers to the diffusion across fibers, is 
believed to be a specific marker for axonal loss and demyelination associated with MS (Oh 
et al., 2004; Lowe et al., 2006; Henry et al., 2003). Relative increase of TD has been shown in 
MS, correlating with demyelination and axonal loss (Song et al., 2005).  This finding 
suggests that fragmented or missing myelin permits greater diffusion of water molecules 
across fibers. Moreover, quantitative variables derived from DTI were found to correlate 
with clinical disability (Filippi & Agosta, 2010).  
Fiber tractography is a diffusion technique based on the directional movement of water, 
which allows the generation of non-invasive three-dimensional images of white matter fiber 
tracts. It is a promising method for in vivo segmentation of the major WM tract fiber 
bundles in the brain (Mori et al., 2002). In MS patients, DT MRI tractography can be used to 
segment clinically eloquent WM pathways, such as the corticospinal tracts, the corpus 
callosum, and the optic radiations and holds promise in enabling visualization and 
quantification of the degree of axonal loss and demyelination in vivo. However, the 
application of DTI tractography in MS is limited by the presence of both focal and diffuse 
alterations of tissue structure, which cause a decrease in anisotropy and consequently an 
increase in uncertainty of the primary eigenvector of the DT (Pagani et al., 2007). Using DT 
MRI tractography, a study in patients with optic neuritis showed reduced connectivity 
values in both left and right optic radiations compared with controls, possibly attributed to 
trans-synaptic degeneration secondary to optic nerve damage (Ciccarelli et al., 2005). DT 
MRI tractography has been also used to identify NAWM fibers at risk for degeneration, 
when they intersect T2-visible lesions (Simon et al., 2006). A recent study found increased 
interthalamic connectivity in patients with early MS as measured by DTI and tractography 
when compared with control subjects, suggesting a possible reactive structural 
reorganization of the fiber tracts within the thalami (Tovar-Moll et al., 2009).  
Technical improvements of tensor models may allow better description of water diffusion in 
more complex architectures such as those with crossing fiber tracts, better segmentation of 
fiber bundles and better understanding of the relationship between tissue structure and 
function. 
4.4 Double inversion recovery imaging     
Double inversion recovery (DIR – i.e. two inversion times are used to suppress the signal 
from both white matter and cerebrospinal fluid) is a novel imaging method that has 
markedly improved the sensitivity of MRI to detect cortical lesions in vivo (Geurts et al., 
2005). Cortical demyelination is an important part of the disease process, especially in more 
advanced stages (Kutzelnigg et al., 2005), and may contribute to the accumulation of 
irreversible disability in MS (Calabrese et al., 2009a,b; Calabrese et al., 2010; Roosendaal et 
al., 2009). Despite improvement, at present only a small number of cortical gray matter 
lesions can be detected with this technique, compared with pathological studies (Calabrese 
et al., 2007; Geurts et al., 2008).  
Cortical lesions have been detected in all the major MS clinical phenotypes, including 
patients with CIS suggestive of MS (Calabrese et al., 2009a, b). Remarkably, cortical lesions 
are more frequently seen in patients with secondary progressive MS than in those with CIS 
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or RRMS. Moreover, patients with early RRMS have a greater number of lesions than 
patients with benign MS (Calabrese et al., 2009a). Longitudinal studies have shown that new 
cortical lesions continue to form in patients with early RRMS (Calabrese et al., 2009a), and in 
those with the progressive disease phenotypes over 1 to 2-year periods of follow-up 
(Calabrese et al., 2009b; Roosendaal et al., 2009). Cortical lesion burden has been associated 
with progression of disability over the subsequent 2 to 3 years in patients with different 
disease phenotypes (Calabrese et al., 2009b), as well as with the severity of cognitive 
impairment in patients with RRMS (Roosendaal et al., 2009).  
DIR sequences at 1.5 T have not been established as yet into the clinical routine probably 
because of the relatively low signal-to-noise ratio values due to the application of two 
inversion pulses, longer acquisition times and higher propensity of artefacts. DIR 
applications at higher magnetic field strengths may overcome these major problems (Wattjes 
& Barkhof, 2009). 
4.5 Functional MRI    
Functional MRI (fMRI) is a non-invasive neuroimaging method that enables visualisation 
not only of the detailed anatomy but also of brain function. It is used to identify changes in 
brain activation in response to various stimuli and in the resting state. The fMRI signal 
reflects blood oxygenation level-dependent (BOLD) alterations associated with activation of 
neural tissue. This mechanism permits the detection of changes in the relationship between 
blood flow and local oxygen consumption. Upon initiating a task, neural activity in the 
involved brain region results in increased blood flow and consequently in increased total 
blood oxygen content (Logothetis et al., 2001; Ogawa et al., 1990). The increased blood 
oxygen produces an increase in the MRI signal, thus allowing demonstration of abnormal 
patterns of brain activation caused by tissue injury.  
fMRI is not used clinically for the diagnosis of MS; rather it is used to provide insight into 
disease progression. The most common finding in fMRI studies is increased extent or 
strength of activation of functional tissue in MS patients compared with controls, implying 
compensatory processes or reorganization of neuronal activation (Lee et al., 2000; Penner et 
al., 2003; Reddy et al., 2000; Rocca et al., 2005). At the initial stages of the disease, an 
increased recruitment of the areas normally involved in the performance of a given task, 
such as the primary sensorimotor cortex and the supplementary motor area is shown (Rocca 
et al., 2003). At later stages, bilateral activation of these regions is first observed, followed by 
a widespread recruitment of additional areas, which are usually recruited by healthy 
subjects in the performance of more complex or novel tasks (Rocca et al., 2005). Similarly, 
fMRI studies investigating various cognitive domains in MS patients have shown altered 
patterns of cortical activation (Audoin et al., 2003; Staffen et al., 2002; Hillary et al., 2003; Li 
et al., 2004; Cader et al., 2006). Moreover a relationship between cortical activation and 
fatigue has been shown in several studies suggesting that the underlying mechanism of this 
common but poorly understood symptom may be the deficiency of neuronal compensation 
(Filippi et al., 2002; White et al., 2009). 
Functional connectivity MRI (resting-state fMRI) is a newer fMRI method that measures low 
frequency oscillations (0.01–0.1 Hz) in BOLD signals across the whole brain during rest, thus 
enabling measurement of functional interactions between brain regions (Cordes et al., 2000). 
Since it studies the strength of network between anatomically separated brain regions, it is 
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considered a promising method to explore disconnectivity effects in MS (van den Heuvel &, 
Hulshoff Pol, 2010). Indeed, decreased levels of functional connectivity of regions of the 
primary motor network have been reported in patients with MS (Lowe et al., 2008). 
Since studies with fMRI have demonstrated consistently functional cortical changes in all 
MS subtypes, this method can be used to assess the role of brain plasticity and cortical 
adaptive changes in limiting the clinical manifestations of demyelination and tissue loss in 
MS and therefore explain the discrepancy between clinical and cMRI findings.  
4.6 High and ultrahigh-field MRI  
Magnet field strengths higher than 1.5 Tesla (T) improve image resolution, signal-to-noise 
ratio and chemical shift. Therefore application of high-field MRI on conventional and 
quantitative MRI methods offers advantages on brain imaging in MS, as it may give new 
insights into the microstructural damage and functional reorganization (Wattjes & Barkhof, 
2009). In patients with established MS, high-field MRI has resulted in a higher detection rate 
of T2 (Wattjes et al., 2009) and gadolinium-enhancing brain (Sicotte et al., 2006) but not 
spinal cord (Stankiewicz et al., 2009) lesions at 3.0T compared with 1.5T. In CIS patients, 
however, 3.0T imaging did not substantially affect evidence for disease dissemination in 
space (Wattjes et al., 2008). 
Ultrahigh-field MRI (referred to as imaging at field strength of 7 Tesla or more) provides 
improved brain lesion load quantification and characterization of the pathological features 
of MS lesions. It is also likely that detection of GM and spinal cord abnormalities could be 
improved by ultrahigh-field MRI (Kangarlu et al., 2007). 
Both high-field and ultra-high field MRI can improve 1H-MRS by providing better 
quantification of metabolites in lesions and the normal-appearing brain tissue (white and 
gray matter) (Srinivasan et al., 2004, 2005, 2009). Magnetisation transfer MRI, diffusion 
tensor MRI, and fMRI studies in MS may also benefit from higher field strengths (Bakshi et 
al., 2008; Wattjes & Barkhof, 2009). Indeed, subtle damage in the NAWM and NAGM 
Ceccarelli ea al., 2007), as well as diffuse microscopic damage in the absence of macroscopic 
MS lesions in the thalamus and basal ganglia has been detected by the use of high-field MRI 
(Tovar-Moll et al., 2009). Finally, higher field MRI might be important for studying iron 
deposition in the grey matter of patients with MS, which has been postulated to contribute 
to neurotoxicity (Stankiewicz et al., 2007).  
4.7 New MR contrast agents  
Conventional MRI allows follow-up of lesion development in time and space. Although in 
clinical practice the number of hyperintense lesions on T2-weighted MRI is considered as 
a biomarker of disease activity in MS, they represent nonspecific tissue alterations. 
Commonly, the identification of gadolinium-DTPA (Gd) enhancing lesions on T1-
weighted scans is considered as evidence for acute inflammation and disruption of the 
BBB. Gd, a lanthanide chelate, is an extracellular contrast agent that requires relatively 
high local concentration to achieve sufficient contrast on MRI. Gadofluorine M (Gf), a new 
Gd-based agent, has been shown in in-vivo experimental studies to have a much higher 
sensitivity than Gd-DTPA in detecting disruption of the BBB on T1-weighted MRI 
(Bendszus et al., 2008).  
The development and application of novel MR contrast agents allowing cellular and 
targeted molecular imaging hold promise in exploring inflammation and its regulation by 
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cell adhesion molecules in MS. Contrast media composed of iron particles [super-
paramagnetic particles of iron oxide (SPIO) and ultrasmall particles of iron oxide (USPIO)] 
are more sensitive compared to Gd-containing agents at similar tissue concentrations (Liu & 
Frank, 2009). The size of SPIO particles is 50–150nm whereas that of USPIO particles is 
approximately 10–50nm. These particles are partly phagocytosed by circulating 
macrophages upon injection. When circulating macrophages are attracted to inflammatory 
lesions, they can be detected in vivo by MRI, since in tissue iron particles shorten both the 
T1 and T2 relaxation time (Vellinga et al., 2008). Several recent studies support the aspect 
that SPIO/USPIO enhanced MRI allows cellular neuroimaging (Baeten et al., 2008; Chin et 
al., 2009). Preliminary studies in RRMS patients have shown that some lesions may enhance 
only with Gd, others only with USPIO, and others with both. Moreover, the same lesions 
can change their pattern of enhancement over time (Vellinga et al., 2008). Furthermore, 
USPIO-enhanced MRI may not only disclose a greater number of ‘active’ MS lesions but 
may also detect subtle and diffuse inflammatory activity in MS patients not visible on 
conventional T2-weighted  MR sequences and unrelated to Gd-DTPA enhancement 
(Vellinga et al., 2009). 
Additionally, novel cellular MR contrast agents such as polyfluorinated nanoemulsions or 
activatable paramagnetic sensors and emerging molecular imaging approaches might give 
new insights into the MS inflammatory process. Myeloperoxidase (MPO) is one of the most 
abundant enzymes secreted by inflammatory cells and, thus, may serve as a marker of 
macrophage inflammation. It has been recently shown in an animal model of EAE that 
myeloperoxidase activity in inflamed tissues can be detected and labelled in vivo by a 
myeloperoxidase sensitive ‘‘smart’’ molecular imaging probe (JW Chen et al., 2008).  
Transferring cellular and targeted molecular imaging approaches from in-vitro to in-vivo 
MRI and subsequently in clinical use holds promise for exploring MS neuroinflammation in 
the future. 
5. Optical techniques  
5.1 Optical coherence tomography (OCT)           
Optical coherence tomography (OCT) is a new, sensitive, non-invasive, transpupilary 
method that allows direct imaging and quantification of the retinal nerve fibre layer (RNFL), 
which  is principally composed of unmyelinated axons. By using an optical interferometer in 
conjunction with a low-coherence light source, OCT detects light reflections within a tissue 
and provides in vivo cross-sectional images at near microscopic resolution (Hrynchak & 
Simpson, 2000; Huang et al., 1991). Recent advances in OCT allow differentiation of major 
retinal layers and analysis of tissue thickness and volume with a resolution of about 3 μm 
(Ko et al., 2004).  
Because the retina is the only place where a tissue layer made up of axons can be imaged 
directly, and the retina and optic nerve are often affected by MS, OCT can be used to assess 
the impact of MS on the retina by measuring the RNFL thickness and macular volume. The 
reductions of RNFL thickness and macular volume are associated with axonal loss and 
secondary retinal ganglion cell loss, respectively. Therefore, OCT shows promise in the 
detection, assessment and monitoring of neurodegeneration in MS (Barkhof et al., 2009; 
Petzold et al., 2010).  
RNFL thinning has been detected with OCT about 3 months after acute optic neuritis. 
Moreover, continuing axonal loss in the affected eye for at least 12 months after optic 
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neuritis has been found, more pronounced the first 6 months after injury (Costello et al., 
2008). In addition, OCT has been shown to be predictive of a clinical outcome (poor visual 
recovery) (Costello et al., 2006). A recent meta-analysis of time domain OCT showed RNFL 
thinning in MS patients, both with and without a history of optic neuritis, more pronounced 
after optic neuritis (Petzold et al., 2010). The estimated RNFL thinning in patients with MS 
has been found to be greater than the extent expected in normal ageing and has been 
attributed to retrograde trans-synaptic degeneration and progressive loss of retinal ganglion 
cells, in addition to the more pronounced thinning observed in case of optic neuritis 
(Petzold et al., 2010). Furthermore, thinning of the RNFL in MS without optic neuritis was 
found to correlate with visual and neurological functioning, as well as with paraclinical data 
(Trip et al., 2005, 2006; Villoslada et al., 2008). 
Macular volume loss has also been reported in patients with MS compared with controls, 
correlating with loss of RNFL (Burkholder et al., 2009; Trip et al., 2006). Recently, a 
subgroup of MS patients with primary retinal pathology characterized by predominant 
macular thinning has been described with the use of OCT, in whom there appears to be 
disproportionate thinning of the inner and outer nuclear retinal layers independent of optic 
nerve pathology. Moreover, these patients were shown to have accelerated disability 
progression, implying that this primary process may be associated with a more aggressive 
form of MS (Saidha et al., 2011). 
OCT could be used for analysis of neurodegeneration in MS as well as for monitoring of 
treatment effects in trials of neuroprotective strategies in MS. Moreover, the integration of 
OCT into MS research could allow insights into the structure–function relations, thus 
improving our understanding of the pathophysiology of the disease. 
6. Conclusion   
Advances in neuroimaging have improved our ability to diagnose and monitor MS and 
have provided insight into the pathophysiology of the disease. Conventional MRI of the 
central nervous system plays a prominent role in establishing the diagnosis of MS and in 
differentiating MS-mimics and demyelinating disease subtypes. Moreover, it allows an 
earlier and accurate diagnosis of the disease, as it can support or even replace some clinical 
criteria. Early diagnosis is essential to allow earlier therapeutic intervention that appears to 
be beneficial on delaying the accumulation of irreversible neurologic damage and 
consequent disability. 
In addition cMRI is a useful tool for monitoring disease progression as it is a sensitive 
imaging biomarker that detects pathological changes prior to the onset of clinical symptoms. 
Conventional MR scans are effective in detecting clinically silent new white matter 
inflammatory lesions. In particular, Gd-enhancing lesions are predictive of future clinical 
relapses. Therefore, cMRI is routinely used for detection of subclinical disease activity and 
for decisions regarding treatment in individual patients. Moreover, most clinical trials 
involving new treatments use MRI parameters as outcome measures to show therapeutic 
effectiveness. Besides Gd-enhancing and T2 lesions, CNS atrophy measurements are being 
increasingly used as primary MRI end point in clinical trials as they have been shown to be 
powerful predictors of clinical impairment, disease progression, and the accumulation of 
long-term physical and neuropsychological disability. 
MRI serves also as a research tool in the study of MS. However, cMRI metrics have a limited 
ability to accurately determine the full extent of inflammatory and neurodegenerative 
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pathological processes in MS. The discrepancy between clinical and MRI evolution in MS 
patients, often referred to as the “clinical–MRI paradox”, has led to a growing interest in 
advanced techniques that can detect the presence of cortical lesions, subtle changes in the 
normal appearing white and gray matter, as well as adaptive functional changes that limit 
the clinical consequences of disease-related injury. The development and application of 
novel MR methods of acquisition and postprocessing aim to provide a more accurate 
characterization of tissue injury including demyelination, remyelination and axonal 
damage. These advanced approaches give also insights into the functional and metabolic 
consequences of MS. Additionally, the combined analysis of different magnetic resonance 
techniques, sensitive toward different aspects of MS, is likely to improve our understanding 
of the mechanisms responsible for the accumulation of irreversible neurological deficits in 
the disease. Emerging applications of these tools may also be useful in measuring the effect 
of therapies. Beyond MRI, novel imaging approaches such as OCT show promise in 
detecting and monitoring neurodegeneration in MS. Nevertheless,  the new techniques and 
analysis procedures need to be refined and validated before they can be properly integrated 
into clinical research and practice. Until that time cMRI metrics will continue to play an 
important role in clinical practice and in clinical trials. Overuse of MRI in clinical practice, 
however, should be avoided. It is important to keep in mind that clinical judgment remains 
essential in the management of the disease and that careful interpretation of the MRI data is 
needed to avoid misdiagnosis. 
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